Patents by Inventor Yves Jacob
Yves Jacob has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11938199Abstract: The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.Type: GrantFiled: April 30, 2018Date of Patent: March 26, 2024Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Yves-Louis Janin, Eloi Paul Coutant, Vincent Hervin, Glwadys Gagnot, Yves Jacob, Sophie Goyard, Thierry Rose
-
Publication number: 20240053339Abstract: Pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein and comprising a heterologous polynucleotide that encodes a label or a recombinase. Compositions or kits comprising the pseudotyped lentiviral vector particles and a mammalian cell expressing an Angiotensin-converting Enzyme 2 (ACE2) protein. Methods of assaying for the presence of neutralizing antibodies against a SARS-CoV-2 S protein in a sample comprising antibodies by providing pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein and comprising a heterologous polynucleotide that encodes a label or a recombinase; providing mammalian cells expressing an ACE2 protein; contacting the mammalian cells expressing the ACE2 protein with the pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein in the presence of a sample comprising antibodies; and assaying for the presence of a label in the mammalian cells.Type: ApplicationFiled: September 21, 2021Publication date: February 15, 2024Inventors: Pierre CHARNEAU, François ANNA, Fabien NEVO, Amandine NOIRAT, Yves JACOB, Phillipe SOUQUE
-
Publication number: 20200129644Abstract: The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.Type: ApplicationFiled: April 30, 2018Publication date: April 30, 2020Inventors: Yves-Louis JANIN, Eloi Paul COUTANT, Vincent HERVIN, Glwadys GAGNOT, Yves JACOB, Sophie GOYARD, Thierry ROSE
-
Patent number: 9682136Abstract: The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA.Type: GrantFiled: January 7, 2015Date of Patent: June 20, 2017Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Chaouki Miled, Frédéric Tangy, Yves Jacob
-
Patent number: 9499799Abstract: The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded RNA viruses (NNV or mononegavirales) from cloned deoxyribonucleic acid (cDNA), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated Schwarz measles virus and various recombinant Schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed.Type: GrantFiled: October 15, 2013Date of Patent: November 22, 2016Assignees: Institut Pasteur, Centre National De La Recherche ScientifiqueInventors: Frederic Tangy, Pierre Charneau, Yves Jacob
-
Publication number: 20150216962Abstract: The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA.Type: ApplicationFiled: January 7, 2015Publication date: August 6, 2015Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEURInventors: Chaouki MILED, Frédéric TANGY, Yves JACOB
-
Patent number: 8980634Abstract: The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA.Type: GrantFiled: January 30, 2009Date of Patent: March 17, 2015Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Chaouki Miled, Frédéric Tangy, Yves Jacob
-
Publication number: 20140051148Abstract: The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded RNA viruses (NNV or mononegavirales) from cloned deoxyribonucleic acid (cDNA), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated Schwarz measles virus and various recombinant Schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed.Type: ApplicationFiled: October 15, 2013Publication date: February 20, 2014Applicants: Institut Pasteur, Centre National De La Recherche ScientifiqueInventors: Frederic Tangy, Pierre Charneau, Yves Jacob
-
Patent number: 8586364Abstract: The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded RNA viruses (NNV or mononegavirales) from cloned deoxyribonucleic acid (cDNA), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated Schwarz measles virus and various recombinant Schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed.Type: GrantFiled: December 21, 2007Date of Patent: November 19, 2013Assignee: Institut PasteurInventors: Frédéric Tangy, Pierre Charneau, Yves Jacob
-
Publication number: 20110311581Abstract: The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA.Type: ApplicationFiled: January 30, 2009Publication date: December 22, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEURInventors: Chaouki Miled, Frédéric Tangy, Yves Jacob
-
Patent number: 8020361Abstract: The transfer machine extends between the die-cut blank erecting station and the discharge conveyor on which the resulting boxes are carried away. It has a carriage that moves lengthwise underneath the sole plate of the various stations over which the box blank progresses. The carriage carries a system of clamps having movable upstream and downstream arms for gripping the blanks and a pusher. Together, the clamps and the pusher are used to move the blanks along the sole plate and push the box onto the discharge conveyor. The arms and the pusher are situated on a plate which is vertically movable relative to the carriage and the height of the projecting part of the upstream arms is greater than the height of the downstream arms and than that of the pushers. The upstream arm couple is hinged to the plate and pivots to allow it to retract upstream relative to the machine and beneath the sole plate. This pivoting of the arm couple is combined with the up-down movement of the plate.Type: GrantFiled: October 10, 2007Date of Patent: September 20, 2011Assignee: Sidel ParticipationsInventors: Bernard Kobierzycki, Pierre-Yves Jacob
-
Publication number: 20110159480Abstract: A method using cells transformed with a construct containing a reporter gene operatively-linked to an interferon stimulated response element for identifying an agent, such as a chemical compound, peptide or polypeptide, which exhibits an interferon-like activity on the interferon stimulated response element (ISRE) and modulates genes activated by activation of the ISRE.Type: ApplicationFiled: December 28, 2009Publication date: June 30, 2011Applicant: INSTITUT PASTEURInventors: Pierre-Olivier Vidalain, Frederic Tangy, Helene Munier-Lehmann, Alexandru Lupan, Marianne Lucas-Hourani, Yves Jacob
-
Publication number: 20100144040Abstract: The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded RNA viruses (NNV or mononegavirales) from cloned deoxyribonucleic acid (cDNA), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated Schwarz measles virus and various recombinant Schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed.Type: ApplicationFiled: December 21, 2007Publication date: June 10, 2010Inventors: Frédéric Tangy, Pierre Charneau, Yves Jacob
-
Publication number: 20100022372Abstract: The transfer machine extends between the die-cut blank erecting station and the discharge conveyor on which the resulting boxes are carried away. It has a carriage that moves lengthwise underneath the sole plate of the various stations over which the box blank progresses. The carriage carries a system of clamps having movable upstream and downstream arms for gripping the blanks and a pusher. Together, the clamps and the pusher are used to move the blanks along the sole plate and push the box onto the discharge conveyor. The arms and the pusher are situated on a plate which is vertically movable relative to the carriage and the height of the projecting part of the upstream arms is greater than the height of the downstream arms and than that of the pushers. The upstream arm couple is hinged to the plate and pivots to allow it to retract upstream relative to the machine and beneath the sole plate. This pivoting of the arm couple is combined with the up-down movement of the plate.Type: ApplicationFiled: October 10, 2007Publication date: January 28, 2010Applicant: SIDEL PARTICIPATIONSInventors: Bernard Kobierzycki, Pierre-Yves Jacob
-
Patent number: 7645455Abstract: The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.Type: GrantFiled: March 22, 2007Date of Patent: January 12, 2010Assignee: Institut PasteurInventors: Yves Jacob, Pierre Perrin, Noël Tordo, Chokri Bahloul
-
Publication number: 20080206282Abstract: The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.Type: ApplicationFiled: March 22, 2007Publication date: August 28, 2008Inventors: Yves Jacob, Pierre Perrin, Noel Tordo, Chokri Bahloul
-
Patent number: 7238672Abstract: The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.Type: GrantFiled: April 17, 2000Date of Patent: July 3, 2007Assignee: Institut PasteurInventors: Yves Jacob, Pierre Perrin, Noël Tordo, Chokri Bahloul
-
Patent number: 7235245Abstract: The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.Type: GrantFiled: June 30, 2003Date of Patent: June 26, 2007Assignee: Institut PasteurInventors: Yves Jacob, Pierre Perrin, Noël Tordo, Chokri Bahloul
-
Publication number: 20050064389Abstract: The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.Type: ApplicationFiled: June 30, 2003Publication date: March 24, 2005Inventors: Yves Jacob, Pierre Perrin, Noel Tordo, Chokri Bahloul
-
Patent number: 6673601Abstract: The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode at least site III of a lyssavirus glycoprotein.Type: GrantFiled: April 14, 2000Date of Patent: January 6, 2004Assignee: Institut PasteurInventors: Yves Jacob, Pierre Perrin, Noël Tordo, Chokri Bahloul